These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31755465)

  • 21. Checkpoint Inhibitor-Induced Hemorrhagic Gastritis with Pembrolizumab.
    Rao BB; Robertson S; Philpott J
    Am J Gastroenterol; 2019 Feb; 114(2):196. PubMed ID: 30353060
    [No Abstract]   [Full Text] [Related]  

  • 22. PEMBROLIZUMAB ADMINISTRATION ASSOCIATED WITH POSTERIOR UVEITIS.
    Aaberg MT; Aaberg TM
    Retin Cases Brief Rep; 2017 Fall; 11(4):348-351. PubMed ID: 27490976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
    Woodbeck R; Metelitsa AI; Naert KA
    Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma.
    Sepúlveda M; Martinez-Hernandez E; Gaba L; Victoria I; Sola-Valls N; Falgàs N; Casanova-Molla J; Graus F
    Muscle Nerve; 2017 Dec; 56(6):E162-E167. PubMed ID: 28439919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM
    Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.
    Aya F; Fernández-Martínez A; Gaba L; Victoria I; Tosca M; Carrera C; Prat A; Arance A
    Immunotherapy; 2016 Jun; 8(6):687-92. PubMed ID: 27115320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Two cases of granuloma annulare under anti-PD1 therapy].
    Charollais R; Aubin F; Roche-Kubler B; Puzenat E
    Ann Dermatol Venereol; 2018 Feb; 145(2):116-119. PubMed ID: 29221649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sudden hearing loss in a melanoma patient on pembrolizumab: an etiology not to be omitted in the differential diagnosis.
    Nader ME; Myers JN; Gidley PW
    J Immunother Cancer; 2017; 5():24. PubMed ID: 28331614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma.
    Durães J; Coutinho I; Mariano A; Geraldo A; Macário MC
    Mult Scler; 2019 Jun; 25(7):1005-1008. PubMed ID: 30311534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient.
    Miserocchi E; Cimminiello C; Mazzola M; Russo V; Modorati GM
    Can J Ophthalmol; 2015 Feb; 50(1):e2-4. PubMed ID: 25677296
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.
    Nardin C; Borot S; Beaudoin MA; Cattin F; Puzenat E; Gauthier AS; Schillo F; Borg C; Aubin F
    Invest New Drugs; 2019 Apr; 37(2):375-377. PubMed ID: 30145624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report.
    Wang JN; Zhang Y; Huang CY; Li K; Yu XB
    BMC Ophthalmol; 2024 Jun; 24(1):240. PubMed ID: 38849786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases.
    Jespersen H; Bjursten S; Ny L; Levin M
    Lancet Oncol; 2018 Jun; 19(6):e327. PubMed ID: 29893264
    [No Abstract]   [Full Text] [Related]  

  • 34. Pembrolizumab-induced Sarcoid-like Reactions during Treatment of Metastatic Melanoma.
    Cheshire SC; Board RE; Lewis AR; Gudur LD; Dobson MJ
    Radiology; 2018 Nov; 289(2):564-567. PubMed ID: 30106351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience.
    Fortes BH; Liou H; Dalvin LA
    Br J Ophthalmol; 2021 Sep; 105(9):1263-1271. PubMed ID: 32830124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
    Parakh S; Nguyen R; Opie JM; Andrews MC
    Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of pembrolizumab for the treatment of melanoma.
    Martin-Liberal J; Kordbacheh T; Larkin J
    Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
    Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
    Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lamotrigine-induced tubulointerstitial nephritis and uveitis-atypical Cogan syndrome.
    Kolomeyer AM; Kodati S
    Eur J Ophthalmol; 2015 Dec; 26(1):e14-6. PubMed ID: 26350991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: Case report.
    Basilious A; Lloyd JC
    Can J Ophthalmol; 2016 Feb; 51(1):e4-6. PubMed ID: 26874174
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.